The molecular biology of Huntington's disease

Psychological Medicine

Volumn 31, Issue 1, 2001, Pages 3-14

  Ho, L W ^a   Carmichael, J ^a   Swartz, J ^a   Wyttenbach, A ^a   Rankin, J ^a   Rubinsztein, D C ^a,b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; AMINO ACID; CYTOSINE; GLUTAMINE; GUANINE; HUNTINGTIN; POLYGLUTAMINE; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AUTOSOMAL DOMINANT INHERITANCE; BRAIN CELL; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; ENERGY METABOLISM; EPIDEMIOLOGICAL DATA; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; METABOLIC DISORDER; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; MOUSE; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN INTERACTION; REVIEW; STRIATE CORTEX; SYMPTOMATOLOGY; TRANSGENIC MOUSE; TREATMENT PLANNING; TRINUCLEOTIDE REPEAT;

ANIMALS; APOPTOSIS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; INCIDENCE; MICE; MICE, TRANSGENIC; MUTATION; NEURONS; OXIDATIVE STRESS; UBIQUITINS;

EID: 0035164243     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0033291799002871     Document Type: Review

References (96)

1. Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: Insights into the genetic evolution of Huntington disease
2. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat
3. Are there multiple pathways in the pathogenesis of Huntington's disease?
4. Biochemical analysis of high molecular weight protein aggregates containing expanded polyglutamine repeat androgen receptor
5. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illness?
6. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
7. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease
8. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length
9. Spinobulbar muscular atrophy
10. 3-Nitropropionic acid animal model and Huntington's disease
11. Clinical correlates of dementia and disability in Huntington's disease
12. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates
13. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum
14. Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease
15. Evidence for proteasome involvement in polyglutamine disease: Localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro
16. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease
17. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture
18. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea
19. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
20. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice
21. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
22. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?
23. Socio-psychiatric consequences of Huntington's disease
24. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
25. Suicide risk in Huntington's disease
26. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes
27. Inactivation of the mouse Huntington's disease gene homolog Hdh
28. Assessment of coenzyme Q10 tolerability in Huntington's disease
29. Searching for function of tissue transglutaminase: Its possible involvement in biochemical pathway of programmed cell death
30. The association of affective disorders with Huntington's disease in a case series and in families
31. Huntington's disease in Maryland: Clinical aspects of racial variation
32. Filamentous nerve cell inclusions in neurodegenerative diseases: Tauopathies and alpha-synucleinopathies
33. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
34. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease
35. Mitochondrial defect in Huntington's disease caudate nucleus
36. Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid)
37. Molecular chaperone functions of heat-shock proteins
38. Quinolinic acid-induced increases in calbindin D28K immunoreactivity in rat striatal neurones in vivo and in vitro mimic the pattern seen in Huntington's disease
39. Amyloid formation by mutant huntingtin: Threshold, progressivity and recruitment of normal polyglutamine proteins
40. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
41. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch
42. 1H NMR spectroscopy
43. A study of psychiatric morbidity in patients with Huntington disease, their relatives and controls. Admissions to psychiatric hospitals in Denmark from 1969 to 1991
44. Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin containing expanded polyglutamine
45. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei
46. A controlled trial of remacemide hydrochloride in Huntington's disease
47. Ataxin-1nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
48. 10
49. Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes
50. Risk factors for suicide in Huntington's disease: A retrospective case controlled study
51. Expression of polyglutamine-expanded huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line
52. 3-Nitropropionic acid - Exogenous animal toxin and possible human striatal toxin
53. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease
54. Kainate-induced degeneration of neostriatal neurons: Dependency upon corticostriatal tract
55. Reduced penetrance of the Huntington's disease mutation
56. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
57. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates
58. Clinical and neuropathologic assessment of severity in Huntington's disease
59. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioural and morphological changes in heterozygotes
60. Caspases: Killer proteins
61. In situ end-labelling detects necrosis of hippocampal pyramidal cells induced by kainic acid
62. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced
63. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
64. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse
65. The role of ataxin-1 nuclear expression and aggregates in SCA1 pathogenesis
66. Intranuclear inclusions of expanded polyglutamine protein in spinocerbellar ataxia type 3
67. Misfolding and aggregation in spinocerebellar ataxia type 3: A role for cellular chaperones in glutamine-repeat disease
68. Huntington disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals
69. Glutamine repeats and neurodegenerative diseases: Molecular aspects
70. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases
71. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models
72. Evidence for a recruitment and sequestration mechanism in Huntington's disease
73. n repeats in parent-offspring pairs with Huntington's disease
74. Huntington's disease
75. Huntington's disease and dentatorubral-pallidoluysian atrophy: Proteins, pathogenesis and pathology
76. Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence
77. Phenotypic characterisation of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats
78. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington's disease
79. Caspase-8 is required for cell death induced by expanded polyglutamine repeats
80. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease
81. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
82. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo
83. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
84. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone
85. Incorporation of glutamine repeats makes protein oligomerize: Implications for neurodegenerative diseases
86. Biochemical abnormalities and excitotoxicity in Huntington's disease brain
87. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions
88. Caspases: Enemies within
89. Juvenile Huntington's disease
90. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract
91. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion
92. Effects of heat shock, Hsp40 and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
93. NMDA receptor losses in putamen from patients with Huntington's disease
94. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homolog